Brokerages Set Hologic, Inc. (NASDAQ:HOLX) Price Target at $89.50

Hologic, Inc. (NASDAQ:HOLX) has received an average rating of “Moderate Buy” from the fifteen analysts that are currently covering the stock, Marketbeat.com reports. Six analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company. The average 12 month price objective among brokerages that have updated their coverage on the stock in the last year is $89.50.

Several brokerages have recently commented on HOLX. Raymond James raised their price objective on shares of Hologic from $93.00 to $95.00 and gave the stock an “outperform” rating in a research report on Tuesday, November 5th. Wolfe Research assumed coverage on shares of Hologic in a research note on Friday, December 13th. They issued a “peer perform” rating for the company. Mizuho cut their price objective on shares of Hologic from $90.00 to $87.00 and set an “outperform” rating on the stock in a research report on Tuesday, November 5th. JPMorgan Chase & Co. raised their target price on Hologic from $92.00 to $94.00 and gave the company an “overweight” rating in a research note on Tuesday, November 5th. Finally, Leerink Partners dropped their price target on Hologic from $95.00 to $90.00 and set an “outperform” rating on the stock in a research note on Tuesday, October 8th.

Insider Buying and Selling at Hologic

In other Hologic news, COO Essex D. Mitchell sold 24,856 shares of the stock in a transaction dated Wednesday, December 4th. The shares were sold at an average price of $76.34, for a total value of $1,897,507.04. Following the completion of the sale, the chief operating officer now owns 27,957 shares in the company, valued at approximately $2,134,237.38. This trade represents a 47.06 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Company insiders own 1.75% of the company’s stock.

Hedge Funds Weigh In On Hologic

Hedge funds and other institutional investors have recently modified their holdings of the business. JPMorgan Chase & Co. lifted its holdings in Hologic by 21.3% during the third quarter. JPMorgan Chase & Co. now owns 1,358,945 shares of the medical equipment provider’s stock worth $110,700,000 after acquiring an additional 238,222 shares during the period. Principal Financial Group Inc. increased its position in shares of Hologic by 3.6% during the 3rd quarter. Principal Financial Group Inc. now owns 269,546 shares of the medical equipment provider’s stock valued at $21,957,000 after purchasing an additional 9,419 shares during the last quarter. Oddo BHF Asset Management Sas bought a new stake in shares of Hologic during the 3rd quarter worth $1,110,000. Franklin Resources Inc. boosted its holdings in shares of Hologic by 171.7% in the 3rd quarter. Franklin Resources Inc. now owns 278,295 shares of the medical equipment provider’s stock worth $22,714,000 after buying an additional 175,855 shares during the last quarter. Finally, Tidal Investments LLC grew its position in Hologic by 60.1% during the third quarter. Tidal Investments LLC now owns 15,351 shares of the medical equipment provider’s stock valued at $1,250,000 after buying an additional 5,764 shares during the period. Hedge funds and other institutional investors own 94.73% of the company’s stock.

Hologic Price Performance

HOLX stock opened at $72.60 on Friday. The company has a quick ratio of 3.03, a current ratio of 3.69 and a debt-to-equity ratio of 0.49. The firm has a market cap of $16.48 billion, a price-to-earnings ratio of 21.80, a PEG ratio of 2.38 and a beta of 0.96. The company’s fifty day simple moving average is $77.61 and its 200 day simple moving average is $78.48. Hologic has a 12-month low of $70.36 and a 12-month high of $84.67.

Hologic (NASDAQ:HOLX) last announced its quarterly earnings data on Monday, November 4th. The medical equipment provider reported $1.01 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $1.01. Hologic had a return on equity of 19.79% and a net margin of 19.59%. The company had revenue of $987.90 million for the quarter, compared to the consensus estimate of $978.25 million. During the same period in the previous year, the business earned $0.89 EPS. The firm’s revenue was up 4.5% compared to the same quarter last year. On average, analysts expect that Hologic will post 4.28 earnings per share for the current year.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.